Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001641172-25-014126
Filing Date
2025-06-06
Accepted
2025-06-06 17:36:43
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 5060
  Complete submission text file 0001641172-25-014126.txt   6728
Mailing Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118
Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118 408-708-9808
Anixa Biosciences Inc (Subject) CIK: 0000715446 (see all company filings)

EIN.: 112622630 | State of Incorp.: DE | Fiscal Year End: 1031
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-36989 | Film No.: 251032201
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O ACACIA RESEARCH CORPORATION 500 NEWPORT CENTER DRIVE, 7TH FLOOR NEWPORT BEACH CA 92660
Business Address
KUMAR AMIT (Filed by) CIK: 0001191905 (see all company filings)

Type: SCHEDULE 13D/A